Nls pharmaceutics ltd. regains full compliance with nasdaq listing requirements

Zurich, switzerland / accesswire / october 28, 2024 / nls pharmaceutics ltd. (nasdaq:nlsp)(nasdaq:nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it has received notice from the nasdaq stock market llc ("nasdaq") informing the company that it has regained full compliance with the bid price requirement in listing rule 5550(a)(2) and the equity requirement in listing rule 5550(b)(1).
NLSP Ratings Summary
NLSP Quant Ranking